How Is Ropeginterferon Alfa-2b Redefining Disease Modification in PV?

added blog Health

2026-05-19 05:04:18 -

Ropeginterferon alfa-2b and molecular remission in PV — the unprecedented therapeutic goal of reducing the JAK2 V617F mutant allele burden below detectable levels in a subset of treated patients — distinguishing ropeginterferon alfa-2b (Besremi, PharmaEssentia) from all other PV treatments that control symptoms and hematologic parameters without affecting the underlying clonal...

0 Comments 0 Shares 55 Views 0 Reviews